195 related articles for article (PubMed ID: 37708024)
21. Identification of differentially expressed genes in uveal melanoma using suppressive subtractive hybridization.
Landreville S; Lupien CB; Vigneault F; Gaudreault M; Mathieu M; Rousseau AP; Guérin SL; Salesse C
Mol Vis; 2011; 17():1324-33. PubMed ID: 21647268
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas.
Field MG; Durante MA; Decatur CL; Tarlan B; Oelschlager KM; Stone JF; Kuznetsov J; Bowcock AM; Kurtenbach S; Harbour JW
Oncotarget; 2016 Sep; 7(37):59209-59219. PubMed ID: 27486988
[TBL] [Abstract][Full Text] [Related]
23. Prognostic impact of chromosomal aberrations and GNAQ, GNA11 and BAP1 mutations in uveal melanoma.
Staby KM; Gravdal K; Mørk SJ; Heegaard S; Vintermyr OK; Krohn J
Acta Ophthalmol; 2018 Feb; 96(1):31-38. PubMed ID: 28444874
[TBL] [Abstract][Full Text] [Related]
24. BAP1 Loss Promotes Suppressive Tumor Immune Microenvironment via Upregulation of PROS1 in Class 2 Uveal Melanomas.
Kaler CJ; Dollar JJ; Cruz AM; Kuznetsoff JN; Sanchez MI; Decatur CL; Licht JD; Smalley KSM; Correa ZM; Kurtenbach S; Harbour JW
Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35954340
[TBL] [Abstract][Full Text] [Related]
25. Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours.
Johansson PA; Brooks K; Newell F; Palmer JM; Wilmott JS; Pritchard AL; Broit N; Wood S; Carlino MS; Leonard C; Koufariotis LT; Nathan V; Beasley AB; Howlie M; Dawson R; Rizos H; Schmidt CW; Long GV; Hamilton H; Kiilgaard JF; Isaacs T; Gray ES; Rolfe OJ; Park JJ; Stark A; Mann GJ; Scolyer RA; Pearson JV; van Baren N; Waddell N; Wadt KW; McGrath LA; Warrier SK; Glasson W; Hayward NK
Nat Commun; 2020 May; 11(1):2408. PubMed ID: 32415113
[TBL] [Abstract][Full Text] [Related]
26. Preferentially Expressed Antigen in Melanoma Immunohistochemistry Labeling in Uveal Melanomas.
Ahmadian SS; Dryden IJ; Naranjo A; Toland A; Cayrol RA; Born DE; Egbert PS; Brown RA; Mruthyunjaya P; Lin JH
Ocul Oncol Pathol; 2022 Jun; 8(2):133-140. PubMed ID: 35959159
[TBL] [Abstract][Full Text] [Related]
27. Intrinsic disorder in PRAME and its role in uveal melanoma.
Antonietti M; Gonzalez DJT; Djulbegovic M; Dayhoff GW; Uversky VN; Shields CL; Karp CL
Cell Commun Signal; 2023 Aug; 21(1):222. PubMed ID: 37626310
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive Genetic Landscape of Uveal Melanoma by Whole-Genome Sequencing.
Royer-Bertrand B; Torsello M; Rimoldi D; El Zaoui I; Cisarova K; Pescini-Gobert R; Raynaud F; Zografos L; Schalenbourg A; Speiser D; Nicolas M; Vallat L; Klein R; Leyvraz S; Ciriello G; Riggi N; Moulin AP; Rivolta C
Am J Hum Genet; 2016 Nov; 99(5):1190-1198. PubMed ID: 27745836
[TBL] [Abstract][Full Text] [Related]
29. BAP1 Loss Is Associated with DNA Methylomic Repatterning in Highly Aggressive Class 2 Uveal Melanomas.
Field MG; Kuznetsov JN; Bussies PL; Cai LZ; Alawa KA; Decatur CL; Kurtenbach S; Harbour JW
Clin Cancer Res; 2019 Sep; 25(18):5663-5673. PubMed ID: 31285370
[TBL] [Abstract][Full Text] [Related]
30. High Cysteinyl Leukotriene Receptor 1 Expression Correlates with Poor Survival of Uveal Melanoma Patients and Cognate Antagonist Drugs Modulate the Growth, Cancer Secretome, and Metabolism of Uveal Melanoma Cells.
Slater K; Heeran AB; Garcia-Mulero S; Kalirai H; Sanz-Pamplona R; Rahman A; Al-Attar N; Helmi M; O'Connell F; Bosch R; Portela A; Villanueva A; Gallagher WM; Jensen LD; Piulats JM; Coupland SE; O'Sullivan J; Kennedy BN
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33066024
[TBL] [Abstract][Full Text] [Related]
31. Differential modulation and prognostic values of immune-escape genes in uveal melanoma.
Basile MS; Mazzon E; Russo A; Mammana S; Longo A; Bonfiglio V; Fallico M; Caltabiano R; Fagone P; Nicoletti F; Avitabile T; Reibaldi M
PLoS One; 2019; 14(1):e0210276. PubMed ID: 30653520
[TBL] [Abstract][Full Text] [Related]
32. Patterns of BAP1 protein expression provide insights into prognostic significance and the biology of uveal melanoma.
Farquhar N; Thornton S; Coupland SE; Coulson JM; Sacco JJ; Krishna Y; Heimann H; Taktak A; Cebulla CM; Abdel-Rahman MH; Kalirai H
J Pathol Clin Res; 2018 Jan; 4(1):26-38. PubMed ID: 29416875
[TBL] [Abstract][Full Text] [Related]
33.
van den Bosch QCC; Nguyen JQN; Brands T; van den Bosch TPP; Verdijk RM; Paridaens D; Naus NC; de Klein A; Kiliç E; Brosens E;
Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35954332
[TBL] [Abstract][Full Text] [Related]
34. BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma.
Matatall KA; Agapova OA; Onken MD; Worley LA; Bowcock AM; Harbour JW
BMC Cancer; 2013 Aug; 13():371. PubMed ID: 23915344
[TBL] [Abstract][Full Text] [Related]
35. BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors.
Han A; Purwin TJ; Bechtel N; Liao C; Chua V; Seifert E; Sato T; Schug ZT; Speicher DW; Harbour JW; Aplin AE
Oncogene; 2021 Jan; 40(3):618-632. PubMed ID: 33208912
[TBL] [Abstract][Full Text] [Related]
36. Identification of canonical NFκB (C-NFκB) pathway in uveal melanoma and their relation with patient outcome.
Singh MK; Singh L; Pushker N; Saini N; Meel R; Chosdol K; Bakhshi S; Sen S; Venkatesh P; Chawla B; Kaur J; Kashyap S
Clin Exp Metastasis; 2019 Jun; 36(3):271-290. PubMed ID: 31069565
[TBL] [Abstract][Full Text] [Related]
37. Minimal contribution of ERK1/2-MAPK signalling towards the maintenance of oncogenic GNAQQ209P-driven uveal melanomas in zebrafish.
Mouti MA; Dee C; Coupland SE; Hurlstone AF
Oncotarget; 2016 Jun; 7(26):39654-39670. PubMed ID: 27166257
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical expression of PRAME is a marker of poor prognosis in uveal melanoma: A clinico-pathologic and immunohistochemical study on a series of 85 cases.
Broggi G; Failla M; Russo A; Longo A; Palicelli A; Zanelli M; Lombardo C; Loreto C; Merolla F; Di Crescenzo RM; Ilardi G; Varricchio S; Staibano S; Caltabiano R
Pathol Res Pract; 2023 Jul; 247():154543. PubMed ID: 37210771
[TBL] [Abstract][Full Text] [Related]
39. Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma.
Chua V; Orloff M; Teh JL; Sugase T; Liao C; Purwin TJ; Lam BQ; Terai M; Ambrosini G; Carvajal RD; Schwartz G; Sato T; Aplin AE
EMBO Mol Med; 2019 Feb; 11(2):. PubMed ID: 30610113
[TBL] [Abstract][Full Text] [Related]
40. BAP1 germline mutation in two first grade family members with uveal melanoma.
Maerker DA; Zeschnigk M; Nelles J; Lohmann DR; Worm K; Bosserhoff AK; Krupar R; Jägle H
Br J Ophthalmol; 2014 Feb; 98(2):224-7. PubMed ID: 24187051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
